Maze Therapeutics, Inc. (MAZE)
| Market Cap | 1.41B +249.2% |
| Revenue (ttm) | 20.00M -88.1% |
| Net Income | -122.54M |
| EPS | -2.49 |
| Shares Out | 55.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,902 |
| Open | 25.95 |
| Previous Close | 26.43 |
| Day's Range | 25.75 - 26.24 |
| 52-Week Range | 8.25 - 53.65 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 68.25 (+167.02%) |
| Earnings Date | May 12, 2026 |
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also deve... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MAZE stock is "Strong Buy." The 12-month stock price target is $68.25, which is an increase of 167.02% from the latest price.
News
Maze Therapeutics reports Q1 EPS (45c), consensus (63c)
Reports Q1 revenue $20M, consensus $8.5M. License revenue was $20M for Q1. No license revenue was recognized for the quarter ended March 31, 2025. License revenue recognized in Q1 of…
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 202...
Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50
The offering includes participation from both new and existing investors including Farallon Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., a large U.S.-based health...
Maze Therapeutics Announces $150 Million Registered Offering
SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its co...
Maze Therapeutics price target lowered to $64 from $68 at Truist
Truist lowered the firm’s price target on Maze Therapeutics (MAZE) to $64 from $68 and keeps a Buy rating on the shares. The firm has updated its outlook following the…
Maze Therapeutics price target raised to $58 from $52 at JPMorgan
JPMorgan raised the firm’s price target on Maze Therapeutics (MAZE) to $58 from $52 and keeps an Overweight rating on the shares. The firm cites an increased probability of success…
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. (NASDAQ: MAZE). The investigation focuses on Maze...
Maze Therapeutics falls -29.8%
Maze Therapeutics (MAZE) is down -29.8%, or -$14.60 to $34.40.
Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James
Raymond James reiterates a Strong Buy rating and $56 price target on Maze Therapeutics (MAZE) after the company announced data from the ongoing Phase 2 HORIZON study of MZE829 in…
Maze Therapeutics falls -33.2%
Maze Therapeutics (MAZE) is down -33.2%, or -$16.28 to $32.72.
Leerink remains bullish on Maze, says Vertex comparison ‘apples to oranges’
Leerink says investors seem to be comparing Maze‘s (MAZE) MZE829 waterfall plot to the one seen with Vertex’s (VRTX) inaxaplin. The firm understands “the desire to compare assets,” though given…
Maze Therapeutics price target raised to $110 from $60 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Maze Therapeutics (MAZE) to $110 from $60 and keeps a Buy rating on the shares. The firm believes Maze’s Phase 2 HORIZON…
Maze Therapeutics reports Q4 EPS (65c), consensus (78c)
Cash, cash equivalents and marketable securities were $360.0 million as of December 31, 2025, compared to $196.8 million as of December 31, 2024. Maze expects that its current cash, cash…
Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data
08:00 EDT Maze Therapeutics (MAZE) up 15% at $56.43 after Q4 results and MZE829 trial data
Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
Maze Therapeutics (MAZE) “announced positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidne...
Maze Therapeutics Transcript: Study result
Phase II HORIZON data show MZE829 achieved a 36% mean reduction in proteinuria in broad AMKD, with 61.8% reduction in FSGS and 48.6% in non-diabetics. The drug was well-tolerated, and early diabetic data are promising. Plans are underway for a pivotal program.
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated ...
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conferenc...
Maze Therapeutics initiated with a Buy at Truist
Truist analyst Danielle Brill initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $68 price target The firm views the company’s pipeline as “differentiated,” with MZE829 for APOL1-med...
Maze Therapeutics price target raised to $58 from $43 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Maze Therapeutics (MAZE) to $58 from $43 and keeps an Outperform rating on the shares. The firm is revisiting its…
Maze Therapeutics initiated with an Outperform at Mizuho
Mizuho initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $97 price target The firm says Maze’s first two drug candidate programs, MZE829 and MZE782, have high revenue…
Maze Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing two key programs: MZE-829 for APOL1-mediated kidney disease, aiming for first-in-class proof of concept with a fully funded phase 2b/3 study, and MZE-782 for PKU and CKD, showing best-in-class early data and planning phase 2 trials. Multiple clinical catalysts are expected this year, supported by strong financials and growing diagnostic infrastructure.
Maze Therapeutics price target raised to $58 from $46 at Guggenheim
Guggenheim raised the firm’s price target on Maze Therapeutics (MAZE) to $58 from $46 and keeps a Buy rating on the shares after the firm discussed the upcoming MZE-829 data…
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pati...
Maze Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Key clinical programs are advancing, with MZE829 data expected soon and MZE782 phase 2 studies for PKU and CKD planned this year. The company’s dual-mechanism approach aims to improve outcomes in kidney and metabolic diseases, with a focus on regulatory pathways and patient impact.